Nasdaq:GRI
GRI Bio, Inc.
A clinical-stage biotech firm leveraging proprietary antibody-drug conjugate platforms to advance early-stage cancer therapies.
Key Metrics
Investment Thesis
Bull Case
GRI offers a high-risk, high-reward opportunity with a unique ADC platform that could generate substantial value upon regulatory approval and commercial launch. The company maintains a healthy cash position relative to its annual burn rate, providing sufficient runway to complete critical Phase 1/2 trials without immediate need for aggressive dilution.
Bear Case
Investors should avoid GRI due to the absence of product revenue and a deepening accumulated deficit of $51.7M that requires continuous capital injections. The company faces substantial competition from established large-cap biotechs with larger balance sheets, making it difficult for GRI to survive long-term without a blockbuster success.
About GRI Bio, Inc.
GRI Bio, Inc. (GRI) is a biotechnology company focused on developing novel therapeutics, primarily within the oncology space, serving patients with solid tumors across North America and Europe.
Analysis
Management Discussion
The company reported a net loss of $12.0M in 2025, consistent with its historical burn patterns seen between $7.0M and $13.0M over the past five years. Despite generating $8.2M in cash reserves, the negative operating cash flow of $10.2M indicates that current financing activities are necessary to sustain operations until clinical milestones are achieved.
Industry Overview
The global oncology market is experiencing rapid growth driven by advancements in targeted therapies and immunotherapies, yet it remains highly competitive with significant barriers to entry. Biotechnology firms in this sector face rigorous regulatory scrutiny and high failure rates during clinical development, necessitating substantial capital reserves and strategic partnerships.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $6.9M | $11.4M | $8.2M | $12.0M |
| Operating Income | $-6.9M | $-11.4M | $-8.2M | $-12.0M |
| R&D | $1.2M | $3.2M | $3.8M | $6.8M |
| G&A | $5.8M | $8.2M | $4.5M | $5.2M |
| Stock-Based Comp | $99.0K | $388.0K | $148.0K | $793.0K |
| Depreciation | — | $4.0K | $4.0K | $4.0K |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $-6.9M | $-11.4M | $-8.2M | $-12.0M |
| Income Tax | $96.0K | $1.6M | $-28.0K | $3.0K |
| Continuing Ops | $-7.0M | $-13.0M | $-8.2M | $-12.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-7.0M | $-13.0M | $-8.2M | $-12.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-7.0M | $-13.0M | $-8.2M | $-12.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $4.2M | $2.9M | $5.6M | $8.6M |
| Cash & Equivalents | $3.8M | $1.8M | $5.0M | $8.2M |
| Prepaid Expenses | $371.0K | $1.1M | $587.0K | $363.0K |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $0 | $22.0K | $124.0K | $74.0K |
| PP&E (Net) | — | $8.0K | $4.0K | $3.0K |
| Operating Leases | — | $14.0K | $120.0K | $71.0K |
| Other LT Assets | — | $0 | $0 | $0 |
| Total Assets | $4.2M | $3.0M | $5.7M | $8.7M |
| Current Liabilities | $1.8M | $2.7M | $1.6M | $2.6M |
| Accounts Payable | $977.0K | $1.4M | $897.0K | $1.8M |
| Current Leases | — | $14.0K | $48.0K | $56.0K |
| Other Current Liab | $122.0K | $3.0K | $0 | $0 |
| Long-Term Liabilities | $0 | $0 | $71.0K | $15.0K |
| LT Operating Leases | — | $0 | $71.0K | $15.0K |
| Other LT Liab | — | $0 | $0 | $0 |
| Total Liabilities | $1.8M | $2.7M | $1.7M | $2.7M |
| Shareholders' Equity | $2.3M | $259.0K | $4.0M | $6.0M |
| Retained Earnings | $-28.9M | $-31.5M | $-39.7M | $-51.7M |
| AOCI | $0 | — | — | — |
| Total L&E | $4.2M | $3.0M | $5.7M | $8.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-7.0M | $-13.0M | $-8.2M | $-12.0M |
| Non-Cash Adjustments | $951.0K | $1.3M | $670.0K | $1.3M |
| Working Capital Changes | $-1.1M | $2.8M | $-1.1M | $423.0K |
| Cash from Operations | $-7.1M | $-9.0M | $-8.6M | $-10.2M |
| Capital Expenditures | — | $8.0K | $0 | $3.0K |
| Cash from Investing | $3.8M | $-8.0K | $0 | $-3.0K |
| Cash from Financing | $3.4M | $10.8M | $11.8M | $13.4M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $79.0K | $1.8M | $3.2M | $3.2M |
| Beginning Cash | $3.7M | $9.0K | $1.8M | $5.0M |
| Ending Cash | $3.8M | $1.8M | $5.0M | $8.2M |
Frequently Asked Questions
How does GRI Bio, Inc. make money?
Oncology Therapeutics (primary focus on solid tumor indications), Preclinical Research Services (limited revenue generation), and Strategic Collaboration Partnerships.
What are the main risks for GRI?
Significant cash burn rate of $12.0M annually with limited revenue generation creating high liquidity risk, dependency on successful clinical trial outcomes to unlock value, and potential dilution from future equity financing to extend the cash runway.
What is GRI's competitive advantage?
Proprietary antibody-drug conjugate (ADC) technology platform with a differentiated payload library, strong partnership ecosystem to fund R&D, and a lean operational structure allowing for capital-efficient drug development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.